BRIEF — Syndax Announces Topline Results From Maxpire Phase 2 Trial Of Axatilimab In Idiopathic Pulmonary Fibrosis

Oct 12 (Reuters) — Syndax Pharmaceuticals, Inc.: Syndax Announces Topline Results From Maxpire Phase 2 Trial Of Axatilimab In Idiopathic Pulmonary Fibrosis Syndax Pharmaceuticals - Will Not Pursue Further Development Of Axatilimab In Ipf Syndax Pharmaceuticals - Axatilimab Well Tolerated With No New Safety Signals In Maxpire Trial Syndax Pharmaceuticals - Axatilimab Continues In Multiple Cgvhd Trials With Results Expected Later This Year And Early 2028 Syndax Pharmaceuticals - Maxpire Phase 2 Trial Of Axatilimab In Ipf Does Not Meet Primary Endpoint Source text:... Further company coverage: SNDX.O (Reuters.Briefs@thomsonreuters.com;)